Evommune (EVMN) Total Current Liabilities (2024 - 2026)

Evommune (EVMN) has reported Total Current Liabilities for 3 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities changed N/A year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $10.6 million (changed N/A YoY), while the FY2025 annual figure was $17.9 million, down 36.0% from the prior year.
• Total Current Liabilities eased to $10.6 million in Q1 2026 per EVMN's latest filing, from $17.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $28.0 million in Q4 2024 and bottomed at $10.4 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $16.7 million across 3 years, with a median of $14.3 million in 2025.
• On a YoY basis, Total Current Liabilities climbed as much as 36.0% in 2025 and fell as far as 36.0% in 2025.
• Evommune's Total Current Liabilities stood at $28.0 million in 2024, then sank by 36.0% to $17.9 million in 2025, then plunged by 40.8% to $10.6 million in 2026.
• Business Quant data shows EVMN's Total Current Liabilities at $10.6 million in Q1 2026, $17.9 million in Q4 2025, and $10.4 million in Q3 2025.